MCID: ESP035
MIFTS: 58

Esophagitis, Eosinophilic, 1

Categories: Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Esophagitis, Eosinophilic, 1

MalaCards integrated aliases for Esophagitis, Eosinophilic, 1:

Name: Esophagitis, Eosinophilic, 1 57 13
Eosinophilic Esophagitis 12 59 37 43 44 15 73
Esophagitis, Eosinophilic; Ee 57
Esophagitis, Eosinophilic 57
Eoe1 57
Eoe 59
Ee 57

Characteristics:

Orphanet epidemiological data:

59
eosinophilic esophagitis
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-5/10000 (Canada),1-5/10000 (Japan),1-5/10000 (Spain),1-5/10000 (Europe),1-5/10000 (United States),1-9/100000 (Switzerland),1-5/10000 (Switzerland); Age of onset: All ages; Age of death: normal life expectancy;

OMIM:

57
Inheritance:
multifactorial

Miscellaneous:
predominantly occurs in young males with high rate of atopic disease


Classifications:



External Ids:

OMIM 57 610247
Disease Ontology 12 DOID:13922
ICD10 33 K20.0
ICD9CM 35 530.13
MeSH 44 D057765
NCIt 50 C27105
SNOMED-CT 68 235599003
Orphanet 59 ORPHA73247
ICD10 via Orphanet 34 K20
MESH via Orphanet 45 D057765
UMLS via Orphanet 74 C0341106
MedGen 42 C0341106
KEGG 37 H01361
UMLS 73 C0341106

Summaries for Esophagitis, Eosinophilic, 1

MedlinePlus : 43 What is eosinophilic esophagitis (EoE)? Eosinophilic esophagitis (EoE) is a chronic disease of the esophagus. Your esophagus is the muscular tube that carries food and liquids from your mouth to the stomach. If you have EoE, white blood cells called eosinophils build up in your esophagus. This causes damage and inflammation, which can cause pain and may lead to trouble swallowing and food getting stuck in your throat. EoE is rare. But because it is a newly recognized disease, more people are now getting diagnosed with it. Some people who think that they have reflux (GERD) may actually have EoE. What causes eosinophilic esophagitis (EoE)? Researchers are not certain about the exact cause of EoE. They think that it is an immune system/allergic reaction to foods or to substances in your environment, such as dust mites, animal dander, pollen, and molds. Certain genes may also play a role in EoE. Who gets eosinophilic esophagitis(EoE)? EoE can affect anyone, but it is more common in people who Are male Are Caucasian Have other allergic diseases, such as hay fever, eczema, asthma and food allergies Have family members with EoE What are the symptoms of eosinophilic esophagitis (EoE)? The most common symptoms of EoE can depend on your age. In infants and toddlers: Feeding problems Vomiting Poor weight gain and growth Reflux that does not get better with medicines In older children: Vomiting Abdominal pain Trouble swallowing, especially with solid foods Reflux that does not get better with medicines Poor appetite In adults: Trouble swallowing, especially with solid foods Food getting stuck in the esophagus Reflux that does not get better with medicines Heartburn Chest pain How is eosinophilic esophagitis (EoE) diagnosed? To diagnose EoE, your doctor will Ask about your symptoms and medical history. Since other conditions can have the same symptoms of EoE, it is important for your doctor to take a thorough history. Do an upper gastrointestinal (GI) endoscopy. An endoscope is a long, flexible tube with a light and camera at the end of it. Your doctor will run the endoscope down your esophagus and look at it. Some signs that you might have EoE include white spots, rings, narrowing, and inflammation in the esophagus. However, not everyone with EoE has those signs, and sometimes they can be signs of a different esophagus disorder. Do a biopsy. During the endoscopy, the doctor will take small tissue samples from your esophagus. The samples will be checked for a high number of eosinophils. This is the only way to make a diagnosis of EoE. Do other tests as needed. You may have blood tests to check for other conditions. If you do have EoE, you may have blood or other types of tests to check for specific allergies. What are the treatments for eosinophilic esophagitis (EoE)? There is no cure for EoE. Treatments can manage your symptoms and prevent further damage. The two main types of treatments are medicines and diet. Medicines used to treat EoE are Steroids, which can help control inflammation. These are usually topical steroids, which you swallow either from an inhaler or as a liquid. Sometimes doctors prescribe oral steroids (pills) to treat people who have serious swallowing problems or weight loss. Acid suppressors such as proton pump inhibitors (PPIs), which may help with reflux symptoms and decrease inflammation. Dietary changes for EoE include Elimination diet. If you are on an elimination diet, you stop eating and drinking certain foods and beverages for several weeks. If you are feeling better, you add the foods back to your diet one at a time. You have repeat endoscopies to see whether or not you are tolerating those foods. There are different types of elimination diets: With one type, you first have an allergy test. Then you stop eating and drinking the foods you are allergic to. For another type, you eliminate foods and drinks that commonly cause allergies, such as dairy products, egg, wheat, soy, peanuts, tree nuts and fish/shellfish. Elemental diet. With this diet, you stop eating and drinking all proteins. Instead, you drink an amino acid formula. Some people who do not like the taste of the formula use a feeding tube instead. If your symptoms and inflammation go away completely, you may be able to try adding foods back one at a time, to see whether you can tolerate them. Which treatment your health care provider suggests depends on different factors, including your age. Some people may use more than one kind of treatment. Researchers are still trying to understand EoE and how best to treat it. If your treatment is not working well enough and you have narrowing of the esophagus, you may need dilation. This is a procedure to stretch the esophagus. This makes it easier for you to swallow.

MalaCards based summary : Esophagitis, Eosinophilic, 1, also known as eosinophilic esophagitis, is related to esophagitis and esophagitis, eosinophilic, 2, and has symptoms including vomiting and epigastric pain. An important gene associated with Esophagitis, Eosinophilic, 1 is BANCR (BRAF-Activated Non-Protein Coding RNA
The lncRNA BANCR was upregulated in EoE and induced in IL-13-treated primary esophageal epithelial cells.We observed EoE-specific upregulation of the long non-coding RNA (lncRNA) BRAF-activated non-coding RNA (BANCR), which was recapitulated by IL-13 treatment of primary esophageal epithelial cells.
Dysfunction Pattern: Regulation [up-regulated]), and among its related pathways/superpathways are Regulation of IFNA signaling and Immune response IFN gamma signaling pathway. The drugs Fluticasone and Budesonide have been mentioned in the context of this disorder. Affiliated tissues include esophagus, testes and t cells, and related phenotypes are edema and dysphagia

Disease Ontology : 12 An esophagitis characterized by inflammation involving eosinophils located in esophagus.

OMIM : 57 Eosinophilic esophagitis (EOE) has an incidence of approximately 1 per 10,000 people. Symptoms include difficulty feeding, failure to thrive, vomiting, epigastric or chest pain, dysphagia, and food impaction. Individuals with EOE are predominantly young males with a high rate of atopic disease, and the diagnosis is made by endoscopy and biopsy findings of isolated eosinophils in the esophagus (summary by Rothenberg et al., 2010). (610247)

Related Diseases for Esophagitis, Eosinophilic, 1

Diseases in the Esophagitis, Eosinophilic, 1 family:

Esophagitis, Eosinophilic, 2

Diseases related to Esophagitis, Eosinophilic, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 133)
# Related Disease Score Top Affiliating Genes
1 esophagitis 27.0 CCL11 CCL26 DSG1 IL13 IL5 POSTN
2 esophagitis, eosinophilic, 2 12.1
3 encephalopathy, ethylmalonic 11.8
4 eosinophilic enteropathy 11.5
5 extraskeletal ewing sarcoma 10.9
6 fungal esophagitis 10.9 ATP12A ATP4A
7 bladder calculus 10.9 ATP12A ATP4A
8 gastrointestinal neuroendocrine benign tumor 10.9 ATP12A ATP4A
9 neonatal candidiasis 10.9 ATP12A ATP4A
10 photoallergic dermatitis 10.9 ATP12A ATP4A
11 squamous papillomatosis 10.9 ATP12A ATP4A
12 acute laryngitis 10.9 ATP12A ATP4A
13 gastroduodenal crohn's disease 10.9 ATP12A ATP4A
14 gastric neuroendocrine neoplasm 10.9 ATP12A ATP4A
15 toxic megacolon 10.9 ATP12A ATP4A
16 aspiration pneumonitis 10.9 ATP12A ATP4A
17 pulmonary fibrosis, idiopathic 10.9
18 cystic fibrosis 10.9
19 macs syndrome 10.9
20 coccidioidomycosis 10.9
21 hemophilia 10.9
22 postsurgical hypothyroidism 10.9 ATP12A ATP4A
23 gastric antral vascular ectasia 10.9 ATP12A ATP4A
24 esophageal candidiasis 10.9 ATP12A ATP4A
25 duodenitis 10.9 ATP12A ATP4A
26 rumination disorder 10.9 ATP12A ATP4A
27 bile reflux 10.9 ATP12A ATP4A
28 granulomatous gastritis 10.9 ATP12A ATP4A
29 active peptic ulcer disease 10.8 ATP12A ATP4A
30 laryngeal disease 10.8 ATP12A ATP4A
31 ischemic neuropathy 10.8 ATP12A ATP4A
32 capillary disease 10.8 ATP12A ATP4A
33 duodenal disease 10.8 ATP12A ATP4A
34 dyskinesia of esophagus 10.8 ATP12A ATP4A
35 congenital disorder of deglycosylation 10.8 ATP12A ATP4A
36 anismus 10.8 ATP12A ATP4A
37 esophageal atresia/tracheoesophageal fistula 10.8 ATP12A ATP4A
38 laryngitis 10.8 ATP12A ATP4A
39 laryngeal tuberculosis 10.8 ATP12A ATP4A
40 lymphocytic colitis 10.8 ATP12A ATP4A
41 clostridium difficile colitis 10.8 ATP12A ATP4A
42 lower urinary tract calculus 10.8 ATP12A ATP4A
43 aspiration pneumonia 10.7 ATP12A ATP4A
44 cytokine deficiency 10.7 IL13 IL5
45 diarrhea 1, secretory chloride, congenital 10.7 ATP12A ATP4A
46 chronic laryngitis 10.7 ATP12A ATP4A
47 angioimmunoblastic lymphadenopathy with dysproteinemia 10.7 IL13 IL5
48 chronic intestinal vascular insufficiency 10.7 ATP12A ATP4A
49 polyposis, skin pigmentation, alopecia, and fingernail changes 10.7 ATP12A ATP4A
50 respiratory syncytial virus infectious disease 10.7 IL13 IL5

Graphical network of the top 20 diseases related to Esophagitis, Eosinophilic, 1:



Diseases related to Esophagitis, Eosinophilic, 1

Symptoms & Phenotypes for Esophagitis, Eosinophilic, 1

Symptoms via clinical synopsis from OMIM:

57
Growth Other:
failure to thrive

Abdomen Gastrointestinal:
dysphagia
vomiting
epigastric pain
difficulty feeding
food impaction
more

Clinical features from OMIM:

610247

Human phenotypes related to Esophagitis, Eosinophilic, 1:

59 32 (show all 14)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 edema 59 32 hallmark (90%) Very frequent (99-80%) HP:0000969
2 dysphagia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002015
3 esophageal stricture 59 32 hallmark (90%) Very frequent (99-80%) HP:0002043
4 esophageal obstruction 59 32 hallmark (90%) Very frequent (99-80%) HP:0005240
5 gastroesophageal reflux 59 32 frequent (33%) Frequent (79-30%) HP:0002020
6 chest pain 59 32 frequent (33%) Frequent (79-30%) HP:0100749
7 spontaneous esophageal perforation 59 32 occasional (7.5%) Occasional (29-5%) HP:0005203
8 abnormality of esophagus morphology 59 Very frequent (99-80%)
9 esophageal stenosis 59 Frequent (79-30%)
10 abnormality of esophagus physiology 59 Occasional (29-5%)
11 failure to thrive 32 HP:0001508
12 vomiting 32 HP:0002013
13 esophagitis 32 HP:0100633
14 epigastric pain 32 HP:0410019

UMLS symptoms related to Esophagitis, Eosinophilic, 1:


vomiting, epigastric pain

Drugs & Therapeutics for Esophagitis, Eosinophilic, 1

Drugs for Esophagitis, Eosinophilic, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluticasone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 90566-53-3 62924
2
Budesonide Approved Phase 4,Phase 3,Phase 2,Not Applicable 51333-22-3 63006 5281004
3
Dexlansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 138530-94-6, 103577-45-3 9578005
4
Lansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 103577-45-3 3883
5
Menthol Approved Phase 4 2216-51-5 16666
6 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
13 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
14 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
18 Cromolyn Sodium Phase 4
19 Antacids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
20 Anti-Ulcer Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
21 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
22 Proton Pump Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
23 Soy Bean Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable
24 Olive Nutraceutical Phase 4
25
Montelukast Approved Phase 3,Phase 1,Not Applicable 158966-92-8 5281040
26
Esomeprazole Approved, Investigational Phase 2, Phase 3,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
27 Leukotriene Antagonists Phase 3,Phase 1,Not Applicable
28
Omalizumab Approved, Investigational Phase 2,Phase 1 242138-07-4
29
Infliximab Approved Phase 2 170277-31-3
30
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
31
Losartan Approved Phase 2 114798-26-4 3961
32
Bethanechol Approved Phase 2 674-38-4 2370
33 Indoleacetic Acids Phase 2
34 Antibodies Phase 2,Phase 1
35 Antibodies, Monoclonal Phase 2,Phase 1
36 Immunoglobulins Phase 2,Phase 1
37 Antirheumatic Agents Phase 2
38 interferons Phase 1, Phase 2
39 Neurotransmitter Agents Phase 2,Not Applicable
40 Pharmaceutical Solutions Phase 2,Not Applicable
41 Angiotensin II Type 1 Receptor Blockers Phase 2
42 Angiotensin Receptor Antagonists Phase 2
43 Angiotensinogen Phase 2
44 Anti-Arrhythmia Agents Phase 2
45 Antihypertensive Agents Phase 2
46 Vasoconstrictor Agents Phase 2
47 mometasone furoate Phase 2
48 Cholinergic Agents Phase 2
49
Lactulose Approved Phase 1 4618-18-2 11333
50
Mannitol Approved, Investigational Phase 1 69-65-8 453 6251

Interventional clinical trials:

(show top 50) (show all 124)
# Name Status NCT ID Phase Drugs
1 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed NCT02371941 Phase 4 oral cromolyn sodium;Placebo
2 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
3 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Active, not recruiting NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
4 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4 Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
5 Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone Unknown status NCT01702701 Phase 3 Montelukast;Fluticasone
6 Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids Unknown status NCT02610816 Phase 2, Phase 3 Flovent (fluticasone propionate)
7 Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis Completed NCT00635089 Phase 3 reslizumab
8 Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis Completed NCT02434029 Phase 3 Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
9 Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Completed NCT00538434 Phase 2, Phase 3
10 A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders Completed NCT00266578 Phase 3 Fluticasone Propionate
11 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed NCT00728481 Phase 2, Phase 3 Esomeprazole;Budesonide
12 Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis Recruiting NCT02493335 Phase 3 Budesonide 0.5mg orodispersible tablet twice daily;Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
13 Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE) Recruiting NCT03245840 Phase 3 Budesonide oral suspension
14 A Placebo- Controlled Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved Recruiting NCT02605837 Phase 3 OBS;Placebo
15 An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE) Recruiting NCT02736409 Phase 3 Oral Budesonide Suspension (OBS);Placebo
16 SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study Recruiting NCT02778867 Phase 2, Phase 3 Flovent
17 Safety and Efficacy of Three Doses of Oral Fluticasone Propionate in Adults With Eosinophilic Esophagitis Not yet recruiting NCT02873468 Phase 2, Phase 3 EMS Fluticasone 1;EMS Fluticasone 2;EMS Fluticasone 3
18 Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis Completed NCT00762073 Phase 2 budesonide;placebo
19 A Study of Flovent in Patients With Eosinophilic Esophagitis Completed NCT00426283 Phase 2 Flovent
20 Budesonide for Eosinophilic Esophagitis Completed NCT00271349 Phase 2 Budesonide
21 Topical Steroid Treatment for Eosinophilic Esophagitis Completed NCT00275561 Phase 2 Fluticasone;Placebo
22 Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis Completed NCT02280616 Phase 2 low dose budesonide tablet;high dose budesonide tablet;high dose budesonide suspension;Placebo
23 Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis Completed NCT02098473 Phase 2 RPC4046;Placebo
24 Proof of Concept Study of OC000459 in Eosinophilic Esophagitis Completed NCT01056783 Phase 2 OC000459;Placebo
25 Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis Completed NCT00638456 Phase 2 Budesonide plus Prevacid;placebo plus Prevacid
26 Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis Completed NCT01386112 Phase 1, Phase 2 EUR-1100;placebo
27 Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis Completed NCT01022970 Phase 2 QAX576 placebo;QAX576
28 Study of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis (EoE) Completed NCT02379052 Phase 2 Dupilumab;Placebo
29 A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab Completed NCT00123630 Phase 2 omalizumab;Placebo
30 Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis Completed NCT00123656 Phase 2 esomeprazole;fluticasone
31 OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension Completed NCT01642212 Phase 2 Oral Budesonide Suspension (MB-9);Placebo
32 Off Label Use of Infliximab in Adult Patients With Severe Eosinophilic Esophagitis Completed NCT00523354 Phase 2 Infliximab
33 Intravenous Mepolizumab In Children With Eosinophilic Esophagitis Completed NCT00358449 Phase 2 mepolizumab
34 An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients Completed NCT00274703 Phase 2 mepolizumab
35 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
36 Omalizumab to Treat Eosinophilic Gastroenteritis Completed NCT00084097 Phase 2 Omalizumab
37 Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Completed NCT00017862 Phase 2 SCH55700
38 Eosinophilic Esophagitis Clinical Therapy Comparison Trial Recruiting NCT01821898 Phase 2 Oral Budesonide
39 Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) Recruiting NCT03191864 Phase 2 APT-1011;Placebo
40 An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) Recruiting NCT03029091 Phase 2 Losartan Potassium
41 A Study of AK002 in Patients With Eosinophilic Gastritis With or Without Eosinophilic Gastroenteritis Recruiting NCT03496571 Phase 2 AK002
42 Benralizumab for Eosinophilic Gastritis Recruiting NCT03473977 Phase 1, Phase 2
43 Milk Patch for Eosinophilic Esophagitis Active, not recruiting NCT02579876 Phase 2 Viaskin Milk 500 mcg;Viaskin Placebo
44 Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD Active, not recruiting NCT01808196 Phase 2 Losartan Potassium
45 Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study. Enrolling by invitation NCT02113267 Phase 2 Mometasone furoate;Placebo
46 Bethanechol for Eosinophilic Esophagitis Terminated NCT02058537 Phase 2 Bethanechol
47 Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Withdrawn NCT01479231 Phase 1, Phase 2 dexlansoprazole
48 Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD Withdrawn NCT01025739 Phase 2
49 Intestinal Permeability in Response to Treatment in Eosinophilic Esophagitis Patients Completed NCT01641913 Phase 1
50 Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model Completed NCT01040598 Phase 1

Search NIH Clinical Center for Esophagitis, Eosinophilic, 1

Cochrane evidence based reviews: eosinophilic esophagitis

Genetic Tests for Esophagitis, Eosinophilic, 1

Anatomical Context for Esophagitis, Eosinophilic, 1

The Foundational Model of Anatomy Ontology organs/tissues related to Esophagitis, Eosinophilic, 1:

19
Esophagus

MalaCards organs/tissues related to Esophagitis, Eosinophilic, 1:

41
Testes, T Cells, Skin, Smooth Muscle, Endothelial, Colon, Lymph Node

Publications for Esophagitis, Eosinophilic, 1

Articles related to Esophagitis, Eosinophilic, 1:

(show top 50) (show all 755)
# Title Authors Year
1
Eosinophilic Esophagitis Is a Late Manifestation of the Allergic March. ( 29954692 )
2018
2
Clinical Translation of Tethered Confocal Microscopy Capsule for Unsedated Diagnosis of Eosinophilic Esophagitis. ( 29422678 )
2018
3
Blind esophageal brushing offers a safe and accurate method to monitor inflammation in children and young adults with eosinophilic esophagitis. ( 29905784 )
2018
4
Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review. ( 29908360 )
2018
5
Airborne and food sensitization patterns in children and adults with eosinophilic esophagitis. ( 29381255 )
2018
6
Epithelial origin of eosinophilic esophagitis. ( 29980278 )
2018
7
Association of mast cells with clinical, endoscopic, and histologic findings in adults with eosinophilic esophagitis. ( 29935026 )
2018
8
Changing Concept of the Prevalence of Eosinophilic Esophagitis: Visible and Hidden Patients. ( 29969848 )
2018
9
Understanding fibrosis in eosinophilic esophagitis: Are we there yet? ( 29377264 )
2018
10
Eosinophilic Esophagitis Through the Flexible Endoscope and the Lens of a Photographer in the Amazon. ( 29427131 )
2018
11
Practice Differences in the Diagnosis and Management of Eosinophilic Esophagitis among Adult and Pediatric Gastroenterologists in Israel. ( 29394215 )
2018
12
Is eosinophilic esophagitis a member of the atopic march? ( 29413330 )
2018
13
Is eosinophilic esophagitis an equivalent of pollen allergic asthma? Analysis of biopsies and therapy guided by component resolved diagnosis. ( 29338961 )
2018
14
Eosinophilic esophagitis and symptoms possibly related to eosinophilic esophagitis in oral immunotherapy. ( 29397272 )
2018
15
Incidence and Prevalence of Pediatric Eosinophilic Esophagitis in Utah Based on a 5-Year Population-Based Study. ( 29935329 )
2018
16
Genetic variants at the 16p13 locus confer risk for eosinophilic esophagitis. ( 29904099 )
2018
17
Eosinophilic Esophagitis: Treatment With Different Doses of Omeprazole in Children Under 16 Years. ( 29939138 )
2018
18
Allergic components of eosinophilic esophagitis. ( 29980277 )
2018
19
Rising incidence and prevalence of adult eosinophilic esophagitis in midwestern Spain (2007-2016). ( 29435311 )
2018
20
Quail egg homogenate alleviates food allergy induced eosinophilic esophagitis like disease through modulating PAR-2 transduction pathway in peanut sensitized mice. ( 29348584 )
2018
21
Trend, clinical presentations and diagnosis of eosinophilic esophagitis in Saudi children. ( 29968888 )
2018
22
Combined and Alternating Topical Steroids and Food Elimination Diet for the Treatment of Eosinophilic Esophagitis. ( 29380175 )
2018
23
Integrin I+M activation and upregulation on esophageal eosinophils and periostin-mediated eosinophil survival in eosinophilic esophagitis. ( 29424023 )
2018
24
Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis. ( 29902649 )
2018
25
A case of Jackhammer esophagus caused by eosinophilic esophagitis in which per-oral endoscopic myotomy resulted in symptom improvement. ( 29790076 )
2018
26
Eosinophilic Esophageal Myositis a Plausible Cause of Histological Changes of Primary Jackhammer Esophagus: A Case Report. ( 29311727 )
2018
27
The Rise and Rise of Eosinophilic Gut Diseases Including Eosinophilic Esophagitis Is Probably Not Explained by the Disappearance of Helicobacter pylori, so Who or What's to Blame? ( 29910462 )
2018
28
Eosinophilic Gastrointestinal Diseases (EGIDs) beyond Eosinophilic Esophagitis (EoE). ( 29940308 )
2018
29
Efficacy of Atopy Patch Testing in Directed Dietary Therapy of Eosinophilic Esophagitis: A Pilot Study. ( 29349695 )
2018
30
Eosinophilic esophagitis and esophageal atresia: coincidence or causality? ( 29333824 )
2018
31
Determinant factors of quality of life in adult patients with eosinophilic esophagitis. ( 29435312 )
2018
32
Obtaining adequate lamina propria for subepithelial fibrosis evaluation in pediatric eosinophilic esophagitis. ( 29309779 )
2018
33
Eosinophilic Esophageal Myositis (EoEM) Causes Jackhammer Esophagus, Rarely Posing a Problem in the Differential Diagnosis of Eosinophilic Esophagitis. ( 29895983 )
2018
34
Maintenance Treatment of Eosinophilic Esophagitis With Swallowed Topical Steroids Alters Disease Course Over A 5-Year Follow-Up Period in Adult Patients. ( 29902648 )
2018
35
Mucosal Impedance: a New Approach to Diagnosing Gastroesophageal Reflux Disease and Eosinophilic Esophagitis. ( 29886566 )
2018
36
Prolonged Time to Diagnosis of Eosinophilic Esophagitis Despite Increasing Knowledge of the Disease. ( 29374615 )
2018
37
What Is the Relationship Between Eosinophilic Esophagitis (EoE) and Aeroallergens? Implications for Allergen Immunotherapy. ( 29909507 )
2018
38
A Gene Expression Panel is Accurate for Diagnosis and Monitoring Treatment of Eosinophilic Esophagitis in Adults. ( 28181994 )
2017
39
HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS IN CHILDREN AND ADOLESCENTS. ( 28954044 )
2017
40
[Eosinophilic esophagitis in children: Evaluation of practices through a multicenter study]. ( 28279614 )
2017
41
Eosinophilic esophagitis: current understanding and evolving concepts. ( 28154800 )
2017
42
Eosinophilic esophagitis: current evidence-based diagnosis and treatment in children and adults. ( 28895370 )
2017
43
Eosinophilic esophagitis in children under the age of 5 years: Clinical characteristics. ( 28865084 )
2017
44
Editorial: Widening the Use of the Functional Lumen Imaging Probe to Kids With Eosinophilic Esophagitis: Esophageal Narrowing is not Just an Adult Problem. ( 28874863 )
2017
45
Health-Related Quality of Life and Costs Associated With Eosinophilic Esophagitis: A Systematic Review. ( 28655543 )
2017
46
Herpes Simplex Virus Esophagitis in Immunocompetent Children: A Harbinger of Eosinophilic Esophagitis? ( 28937540 )
2017
47
Adrenal Insufficiency in Pediatric Eosinophilic Esophagitis Patients Treated with Swallowed Topical Steroids. ( 29062584 )
2017
48
Clinical Applications of the Eosinophilic Esophagitis Diagnostic Panel. ( 28770203 )
2017
49
Elevated Serum Tissue Transglutaminase Antibodies in Children With Eosinophilic Esophagitis. ( 28644352 )
2017
50
Abnormal Responses to Local Esophageal Food Allergen Injections in Adult Patients with Eosinophilic Esophagitis. ( 28870530 )
2017

Variations for Esophagitis, Eosinophilic, 1

Expression for Esophagitis, Eosinophilic, 1

Search GEO for disease gene expression data for Esophagitis, Eosinophilic, 1.

Pathways for Esophagitis, Eosinophilic, 1

GO Terms for Esophagitis, Eosinophilic, 1

Cellular components related to Esophagitis, Eosinophilic, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.17 ATP4A CCL11 CCL26 IL13 IL5 POSTN

Biological processes related to Esophagitis, Eosinophilic, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.73 CCL11 CCL26 IL13 IL5
2 cytokine-mediated signaling pathway GO:0019221 9.62 CCL11 IL13 IL5 STAT6
3 cellular response to tumor necrosis factor GO:0071356 9.58 CCL11 CCL26 POSTN
4 ATP hydrolysis coupled proton transport GO:0015991 9.48 ATP12A ATP4A
5 eosinophil chemotaxis GO:0048245 9.46 CCL11 CCL26
6 cellular sodium ion homeostasis GO:0006883 9.37 ATP12A ATP4A
7 cellular potassium ion homeostasis GO:0030007 9.26 ATP12A ATP4A
8 sodium ion export across plasma membrane GO:0036376 9.16 ATP12A ATP4A
9 regulation of signaling receptor activity GO:0010469 9.02 CCL11 CCL26 IL13 IL5 TSLP
10 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 8.96 ATP12A ATP4A

Molecular functions related to Esophagitis, Eosinophilic, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase activity GO:0005391 9.26 ATP12A ATP4A
2 CCR3 chemokine receptor binding GO:0031728 9.16 CCL11 CCL26
3 cytokine activity GO:0005125 9.02 CCL11 CCL26 IL13 IL5 TSLP
4 potassium:proton exchanging ATPase activity GO:0008900 8.96 ATP12A ATP4A

Sources for Esophagitis, Eosinophilic, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....